SMTI Stock Analysis: Buy, Sell, or Hold?
SMTI - Sanara MedTech Inc. Common Stock
$22.89
1.14 (5.24%)
▲
5d:
+0.88%
30d:
-1.21%
90d:
+26.6%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When SMTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SMTI shows positive signals but monitor for confirmation. Market pricing in 5.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: SMTI shows positive signals but monitor for confirmation. Market pricing in 5.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$26.29
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$16.32
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SMTI is currently trading at $22.89, which is considered slightly high relative to its 30-day fair value range of $21.52 to $23.12. From a valuation perspective, the stock is trading at a premium (Forward PE: 40.3) compared to its historical average (34.2). At these levels, the market is pricing in 5.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SMTI is showing sideways momentum. Immediate support is located at $20.91, while resistance sits at $23.92. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.33 (+57.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SMTI is showing sideways momentum. Immediate support is located at $20.91, while resistance sits at $23.92. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $34.33 (+57.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$21.52 -
$23.12
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.0%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.2%)
- BULLISH: Trading 57.9% below Wall St target ($34.33)
- NEUTRAL: Trading at premium valuation - market expects 5.6% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$21.52 -
$23.12
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$20.91
Resistance Level
$23.92
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
40.28
Wall Street Target
$34.33
(+57.9%)
Revenue Growth (YoY)
18.6%
Profit Margin
-31.2%
Valuation Premium vs History
+5.6% premium
PE vs Historical
40.3 vs 34.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.6%
(market-implied from PE analysis)
1-Year Target
$22.97
(+6%)
2-Year Target
$24.25
(+12%)
3-Year Target
$25.61
(+18%)
3-Yr Target (if PE normalizes)
(PE: 40→34)
PE COMPRESSION
$21.75
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 40.3, Growth: 200.0%)
$73.41
(+238%)
Base:
(SPY PE: 21.8, Growth: 200.0%)
$39.69
(+83%)
Bear:
(PE: 18.5, Growth: 200.0%)
$33.74
(+55%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (135x PE), but valuation improves significantly next year (40x PE) as earnings recover.
Forward PE: 135.14 | Forward EPS (Implied): $0.16
Bull Case
$26.26
(+21%)
Analyst growth 15.0%, PE expands to 141.9
Base Case
$21.75
(0%)
Market implied 0.0%, PE stable at 135.1
Bear Case
$16.64
(-24%)
Severe decline -15.0%, PE contracts to 121.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 4:58 PM ET
Data refreshes hourly during market hours. Next update: 5:58 PM
Data refreshes hourly during market hours. Next update: 5:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SMTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$565 | 59 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$88 | 60 BUY |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
13 analysts |
$359 | 69 BUY |
|
RMD
ResMed Inc |
BUY
19 analysts |
$262 | 67 BUY |
|
RGEN
Repligen Corporation |
STRONG BUY
19 analysts |
$176 | 55 HOLD |
